SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction inj… Read more
SanBio Company Limited (SNBIF) - Net Assets
Latest net assets as of July 2025: $1.29 Billion USD
Based on the latest financial reports, SanBio Company Limited (SNBIF) has net assets worth $1.29 Billion USD as of July 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.22 Billion) and total liabilities ($1.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.29 Billion |
| % of Total Assets | 40.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -78.89% |
| 10-Year Change | -72.3% |
| Growth Volatility | 308.29 |
SanBio Company Limited - Net Assets Trend (2014–2025)
This chart illustrates how SanBio Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SanBio Company Limited (2014–2025)
The table below shows the annual net assets of SanBio Company Limited from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $1.76 Billion | -36.87% |
| 2024-01-31 | $2.79 Billion | -36.95% |
| 2023-01-31 | $4.43 Billion | +117.62% |
| 2022-01-31 | $2.04 Billion | -75.63% |
| 2021-01-31 | $8.35 Billion | -23.61% |
| 2020-01-31 | $10.93 Billion | +22.69% |
| 2019-01-31 | $8.91 Billion | +946.90% |
| 2018-01-31 | $851.00 Million | -81.48% |
| 2017-01-31 | $4.59 Billion | -27.81% |
| 2016-01-31 | $6.37 Billion | +7332.95% |
| 2015-01-31 | $-88.00 Million | +95.52% |
| 2014-01-31 | $-1.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SanBio Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 502709900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $2.46 Billion | 139.64% |
| Total Equity | $1.76 Billion | 100.00% |
SanBio Company Limited Competitors by Market Cap
The table below lists competitors of SanBio Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hengxin Mobile Business
SHE:300081
|
$354.56 Million |
|
RWS Holdings plc
PINK:RWSPF
|
$354.56 Million |
|
Hootech Inc.
SHE:301026
|
$354.60 Million |
|
Sk Gas
KO:018670
|
$354.68 Million |
|
AngioDynamics Inc
NASDAQ:ANGO
|
$354.40 Million |
|
Natural Grocers by Vitamin Cottage Inc
NYSE:NGVC
|
$354.38 Million |
|
Tremor International Ltd
PINK:TTTPF
|
$354.16 Million |
|
Intrum AB (publ)
PINK:ITJTY
|
$354.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SanBio Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,792,398,000 to 1,762,922,000, a change of -1,029,476,000 (-36.9%).
- Net loss of 2,882,885,000 reduced equity.
- New share issuances of 2,372,805,000 increased equity.
- Other factors decreased equity by 519,396,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.88 Billion | -163.53% |
| Share Issuances | $2.37 Billion | +134.6% |
| Other Changes | $-519.40 Million | -29.46% |
| Total Change | $- | -36.87% |
Book Value vs Market Value Analysis
This analysis compares SanBio Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.26x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-01-31 | $0.00 | $6.55 | x |
| 2017-01-31 | $0.00 | $6.55 | x |
| 2018-01-31 | $0.00 | $6.55 | x |
| 2019-01-31 | $179.14 | $6.55 | x |
| 2020-01-31 | $211.07 | $6.55 | x |
| 2021-01-31 | $161.24 | $6.55 | x |
| 2022-01-31 | $39.29 | $6.55 | x |
| 2023-01-31 | $72.01 | $6.55 | x |
| 2024-01-31 | $41.11 | $6.55 | x |
| 2025-01-31 | $24.86 | $6.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SanBio Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -163.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.96x
- Recent ROE (-163.53%) is below the historical average (-104.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -288.73% | 0.43x | 0.00x | $-392.70 Million |
| 2015 | 0.00% | 53.76% | 1.84x | 0.00x | $1.74 Billion |
| 2016 | -15.52% | -84.16% | 0.14x | 1.30x | $-1.62 Billion |
| 2017 | -39.93% | -193.36% | 0.15x | 1.37x | $-2.29 Billion |
| 2018 | -462.98% | -804.08% | 0.09x | 6.10x | $-4.03 Billion |
| 2019 | -32.78% | -393.81% | 0.05x | 1.57x | $-3.81 Billion |
| 2020 | -47.19% | -1153.27% | 0.03x | 1.43x | $-6.25 Billion |
| 2021 | -40.55% | -14797.11% | 0.00x | 1.60x | $-4.22 Billion |
| 2022 | -229.85% | 0.00% | 0.00x | 2.71x | $-4.88 Billion |
| 2023 | -125.53% | 0.00% | 0.00x | 1.59x | $-6.00 Billion |
| 2024 | -94.70% | 0.00% | 0.00x | 1.81x | $-2.92 Billion |
| 2025 | -163.53% | 0.00% | 0.00x | 1.96x | $-3.06 Billion |
Industry Comparison
This section compares SanBio Company Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SanBio Company Limited (SNBIF) | $1.29 Billion | 0.00% | 1.49x | $354.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |